PLK1及其在KRAS突变型结直肠癌不断演变格局中的作用。（注：原文中“-mutated”推测应该是“KRAS-mutated”之类，这里按常见情况补充完整翻译） - Suppr

Suppr

超能文献

PLK1 and its role in the evolving landscape of -mutated colorectal cancer.

作者信息

Harvey Harry, Chen Eric Xueyu

机构信息

Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.

出版信息

J Gastrointest Oncol. 2024 Aug 31;15(4):1987-1992. doi: 10.21037/jgo-24-323. Epub 2024 Aug 19.

DOI:10.21037/jgo-24-323

PMID:39279930

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11399817/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c3b/11399817/f70e72e914fa/jgo-15-04-1987-f1.jpg

相似文献

PLK1 and its role in the evolving landscape of -mutated colorectal cancer.PLK1及其在KRAS突变型结直肠癌不断演变格局中的作用。（注：原文中“-mutated”推测应该是“KRAS-mutated”之类，这里按常见情况补充完整翻译）

J Gastrointest Oncol. 2024 Aug 31;15(4):1987-1992. doi: 10.21037/jgo-24-323. Epub 2024 Aug 19.

Impact of anatomical liver resection on patient survival in KRAS-wild-type colorectal liver metastasis: A multicenter retrospective study.KRAS 野生型结直肠癌肝转移行解剖性肝切除术对患者生存的影响：一项多中心回顾性研究。

Surgery. 2022 Oct;172(4):1133-1140. doi: 10.1016/j.surg.2022.05.014. Epub 2022 Aug 12.

Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.针对共识分子亚型 3 以及结直肠癌治疗中 KRAS 基因突变的能量代谢进行靶向治疗的策略。

J Cell Physiol. 2019 May;234(5):5601-5612. doi: 10.1002/jcp.27388. Epub 2018 Oct 20.

Strategies for targeting energy metabolism in Kirsten rat sarcoma viral oncogene homolog -mutant colorectal cancer.针对 Kirsten 大鼠肉瘤病毒癌基因同源物突变型结直肠癌中能量代谢的策略。

J Cell Biochem. 2019 Feb;120(2):1106-1121. doi: 10.1002/jcb.27558. Epub 2018 Oct 26.

Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong and Anti-Tumorigenic Activity in Kirsten Rat Sarcoma-Mutated Cancers.由聚合物胶束介导的抗 Kirsten 大鼠肉瘤抗体的细胞内递送在 Kirsten 大鼠肉瘤突变型癌症中发挥强大的抗肿瘤活性。

ACS Appl Mater Interfaces. 2023 Mar 1;15(8):10398-10413. doi: 10.1021/acsami.2c19897. Epub 2023 Feb 16.

The relationship of KRAS expression with KRAS status, prognosis, and tumor-infiltrated T lymphocytes in colorectal cancer.KRAS表达与结直肠癌中KRAS状态、预后及肿瘤浸润性T淋巴细胞的关系。

Therap Adv Gastroenterol. 2024 May 15;17:17562848241249387. doi: 10.1177/17562848241249387. eCollection 2024.

Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer.Kirsten 大鼠肉瘤病毒（+）非小细胞肺癌的新兴疗法

Cancers (Basel). 2024 Apr 9;16(8):1447. doi: 10.3390/cancers16081447.

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.致癌性 KRAS 在结直肠癌的预后、诊断和治疗中的作用。

Mol Cancer. 2021 Nov 6;20(1):143. doi: 10.1186/s12943-021-01441-4.

KRAS mutations and subtyping in colorectal cancer in Jordanian patients.约旦患者结直肠癌中的KRAS突变与亚型分析

Oncol Lett. 2012 Oct;4(4):705-710. doi: 10.3892/ol.2012.785. Epub 2012 Jul 4.

The Therapeutic Landscape for -Mutated Colorectal Cancers.KRAS 突变型结直肠癌的治疗前景

Cancers (Basel). 2023 Apr 19;15(8):2375. doi: 10.3390/cancers15082375.

引用本文的文献

The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models.选择性WEE1抑制剂阿泽诺塞替布在临床前模型中与KRASG12C抑制剂显示出协同抗肿瘤活性。

Cancer Res Commun. 2025 Feb 1;5(2):240-252. doi: 10.1158/2767-9764.CRC-24-0411.

本文引用的文献

Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study.Onvansertib 联合 FOLFIRI 和贝伐珠单抗二线治疗 KRAS 突变转移性结直肠癌：一项 Ib 期临床研究。

Clin Cancer Res. 2024 May 15;30(10):2039-2047. doi: 10.1158/1078-0432.CCR-23-3053.

Sotorasib with panitumumab in chemotherapy-refractory KRAS-mutated colorectal cancer: a phase 1b trial.索托拉西布联合帕尼单抗治疗化疗耐药 KRAS 突变型结直肠癌：一项 1b 期试验。

Nat Med. 2024 Jan;30(1):265-270. doi: 10.1038/s41591-023-02717-6. Epub 2024 Jan 4.

Polθ is phosphorylated by PLK1 to repair double-strand breaks in mitosis.Polθ 通过 PLK1 的磷酸化来修复有丝分裂中的双链断裂。

Nature. 2023 Sep;621(7978):415-422. doi: 10.1038/s41586-023-06506-6. Epub 2023 Sep 6.

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated G12C.在携带突变 G12C 的结直肠癌中，阿达格拉西布联合或不联合西妥昔单抗。

N Engl J Med. 2023 Jan 5;388(1):44-54. doi: 10.1056/NEJMoa2212419. Epub 2022 Dec 21.

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.双重抑制 MEK 和 CDK4/6 靶向治疗 RAS 突变型结直肠癌。

Cancer Res. 2022 Sep 16;82(18):3335-3344. doi: 10.1158/0008-5472.CAN-22-0198.

Sotorasib for previously treated colorectal cancers with KRAS mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.索托拉西布治疗 KRAS 突变的既往治疗过的结直肠癌（CodeBreaK100）：一项单臂、2 期试验的预先指定分析。

Lancet Oncol. 2022 Jan;23(1):115-124. doi: 10.1016/S1470-2045(21)00605-7. Epub 2021 Dec 15.

Sotorasib for Lung Cancers with p.G12C Mutation.索托拉西布治疗 p.G12C 突变型肺癌。

N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4.

KRAS: From undruggable to a druggable Cancer Target.KRAS：从不可成药到可成药的癌症靶点。

Cancer Treat Rev. 2020 Sep;89:102070. doi: 10.1016/j.ctrv.2020.102070. Epub 2020 Jul 15.

A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors.GGTI-2418（法尼基转移酶 I 抑制剂）治疗晚期实体瘤患者的 I 期研究。

Target Oncol. 2019 Oct;14(5):613-618. doi: 10.1007/s11523-019-00661-5.

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.FOLFOXIRI 联合贝伐珠单抗对比 FOLFIRI 联合贝伐珠单抗一线治疗转移性结直肠癌患者：开放标签、3 期 TRIBE 研究的总生存更新及分子亚组分析。

Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验